Clinical trials: Response Evaluation
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major…
- Trial name
- CLARITY (NCT07484217)
- Testing
- Solriamfetol 150 MG
- Where
- 40 sites in United States
- Volunteers
- 508 people
- Sponsor
- Axsome Therapeutics, Inc.
AIDS, AIDS Vaccines
Study to Optimize the Quality of Samples for Cell-mediated Immunity (CMI) in ART-naïve HIV-1-infected Subjects
The purpose of this study is to investigate a combined set of parameters deemed to impact the quality of CMI analyses in terms of the proportion of viable lymphocytes in antiretroviral therapy-naïve HIV-1 infected subjects.
- Trial name
- NCT01610427
- Testing
- Blood sample collection
- Where
- Belgium
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009, When Administered to Non-Elderly Adult and Elderly Subjects
Annual trial for registration influenza vaccine with the strain composition for season 2008/2009
- Trial name
- NCT00748150
- Testing
- Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
- Where
- United Kingdom
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
The aim of this study is to support development of asciminib in the pediatric population (1 to < 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose…
- Trial name
- NCT07354074
- Testing
- Asciminib single agent
- Where
- 34 sites in United States, Australia and 13 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Complicated Skin and Soft Tissue Infection
Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.
The purpose of this study is to evaluate the effects of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in treatment of patients with complicated bacterial skin and soft tissue infections.
- Trial name
- NCT02202135
- Testing
- Ceftaroline fosamil, Vancomycin, Aztreonam
- Where
- 22 sites in Argentina, Brazil and 11 more
- Volunteers
- 4 people
- Sponsor
- Pfizer
Hepatitis C, Anemia
A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)
The purpose of this study was to describe the time course and extent of hemoglobin (Hb) changes and the erythropoietic response to PEG-IFN/RBV-induced anemia In HCV-infected subjects.
- Trial name
- NCT00328549
- Testing
- Pegylated Interferon and Ribavirin
- Volunteers
- 105 people
- Sponsor
- Ortho Biotech Products, L.P.
Bone Marrow Transplantation
An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers
Ronacaleret is an orally administered CaSR antagonist which has previously been demonstrated to transiently increase PTH in both animals and humans.
- Trial name
- NCT01466335
- Testing
- Ronacaleret (100mg tablet)
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C
Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed
SCV-07 (γ-D-glutamyl-L-tryptophan) is a new immunomodulatory compound that has been developed and patented both for composition and immunomodulatory use and is a synthetic dipeptide.
- Trial name
- NCT00968357
- Testing
- SCV-07
- Where
- 16 sites in United States
- Volunteers
- 40 people
- Sponsor
- SciClone Pharmaceuticals
Solid Cancer
An Exploratory Clinical Study to Evaluate the Safety, Tolerability, Immune Response and Preliminary Efficacy of LM103 Injection in Combination With PD-1 in Patients With Advanced Solid Tumours
This is an exploratory clinical study evaluating the safety, tolerability, immune response and preliminary efficacy of LM103 Injection in combination with PD-1 in patients with advanced solid tumours.
- Trial name
- NCT06697665
- Testing
- LM103
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Non Small Cell Lung Cancer, Healthy
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients.
- Trial name
- PROPHETIC (NCT05736029)
- Testing
- blood, stool and tissue samples collection
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- OncoHost Ltd.
Rheumatoid Arthritis
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy
This study was an extension to study MA21573 [NCT00750880], which was an open label single arm study to investigate the safety, tolerability and efficacy of tocilizumab monotherapy, or combination therapy with non-biological…
- Trial name
- NCT00883753
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 171 sites in Australia, Canada and 12 more
- Volunteers
- 934 people
- Sponsor
- Hoffmann-La Roche
Psoriasis
A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
This single arm study will evaluate the efficacy and safety of sequential treatment with Diavobet (betamethasone propionate 0.5mg/g plus calcipotriol hydrate 50 micrograms/g) once daily for 4 weeks followed by Daivonex…
- Trial name
- NCT00437619
- Testing
- calcipotriol hydrate [Daivonex]
- Where
- 10 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
Cervical Dystonia
Assessment of Long-term Clinical Response to BoNT in Cervical Dystonia
The goal of this retrospective, international, multi-center chart abstraction is to learn about the long-term impact of product-specific immunogenicity-related factors in different botulinum neurotoxin type A formulations in…
- Trial name
- RELY-CD (NCT05884528)
- Testing
- CC BoNT/A, CF BoNT/A, CF to CC BoNT/A
- Where
- Germany
- Volunteers
- 270 people
- Sponsor
- Merz Therapeutics GmbH
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
This is a phase I/II pediatric dose-ranging study that will evaluate the safety, tolerability, clinical response, pharmacokinetics and pharmacodynamics of midostaurin in patients <18 years of age who have relapsed or refractory…
- Trial name
- NCT00866281
- Testing
- midostaurin
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasm Female
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant…
- Trial name
- BREVITY (NCT03524430)
- Testing
- Core needle biopsy
- Where
- 7 sites in United States, Canada and 5 more
- Volunteers
- 801 people
- Sponsor
- Rna Diagnostics Inc.
COVID-19, SARS-CoV-2 Infection
Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins in COVID-19 Patients
SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has negatively impacted global health and requires more research to develop better tests and to improve disease treatment.
- Trial name
- SARS-CoV-2 (NCT04465981)
- Testing
- Sampling
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- INanoBio Inc.
Hepatocellular Carcinoma
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or…
- Trial name
- NCT03867084
- Testing
- Pembrolizumab
- Where
- 249 sites in United States, Argentina and 29 more
- Volunteers
- 959 people
- Sponsor
- Merck Sharp & Dohme LLC
Psychological Stress
Essential Oil Inhalation and Acute Stress Response in Healthy Adults
This randomized, double-blind, placebo-controlled study evaluates the acute physiological and subjective responses to essential oil inhalation in healthy adults.
- Trial name
- DMA (NCT07473544)
- Testing
- Essential Oil Inhalation
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- dōTERRA International
Epstein Barr Virus (EBV) Infection
Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).
To evaluate the safety, immune-response and efficacy of GSK Biologicals' EBV vaccine in a population at risk of developing infectious mononucleosis.
- Trial name
- NCT00430534
- Testing
- EBV vaccine (268664)
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Henogen
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor
This study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis who have had an inadequate response to one prior anti-TNF alpha inhibitor.
- Trial name
- NCT02079532
- Testing
- rituximab [MabThera]
- Where
- 69 sites in Germany
- Volunteers
- 302 people
- Sponsor
- Hoffmann-La Roche